Drug releasing coatings for medical devices
The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.
1. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a dried coating layer overlying an exterior surface of the medical device, the dried coating layer comprising a hydrophobic therapeutic agent and a first additive, and a second additive, wherein:
the hydrophobic therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof; and
the first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, and combinations thereof; and
the second additive is selected from the group consisting of sorbitol, sorbitan, xylitol, gluconolactone, and combinations thereof.
2. The medical device of claim 1 , wherein the dried coating layer further comprises an antioxidant comprising propyl gallate.
3. The medical device of claim 1 , wherein:
the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof.
4. The medical device of claim 1 , wherein:
the first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and
the second additive is selected from the group consisting of sorbitol, gluconolactone, and combinations thereof.
5. The medical device of claim 1 , wherein:
the first additive is PEG-20 sorbitan monolaurate or PEG-20 sorbitan monooleate; and
the second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.
6. The medical device of claim 1 , wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.
7. The medical device of claim 1 , wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.
8. The medical device of claim 1 , wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.
9. The medical device of claim 1 , wherein:
the medical device is a balloon catheter;
the hydrophobic therapeutic agent is paclitaxel; and
the dried coating layer further comprises an antioxidant comprising propyl gallate.
10. The medical device of claim 9 , wherein the balloon catheter is a cutting balloon catheter or a scoring balloon catheter.
11. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising a dried coating layer overlying an exterior surface of the medical device, the dried coating layer consisting essentially of a hydrophobic therapeutic agent and a combination of a water-soluble first additive and a water-soluble second additive, wherein:
the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;
the water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, and combinations thereof; and
the water-soluble second additive is selected from the group consisting of sorbitol, xylitol, gluconolactone, and combinations thereof.
12. The medical device of claim 11 , wherein the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles.
13. The medical device of claim 11 , wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is gluconolactone.
14. The medical device of claim 11 , wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is sorbitol or xylitol.
15. The medical device of claim 11 , wherein:
the water-soluble first additive is PEG-20 sorbitan monooleate; and
the water-soluble second additive is gluconolactone.
16. The medical device of claim 11 , wherein:
the water-soluble first additive is PEG-20 sorbitan monooleate; and
the water-soluble second additive is sorbitol or xylitol.
17. The medical device of claim 11 , wherein:
the water-soluble first additive is PEG-20 sorbitan monolaurate; and
the water-soluble second additive is lactobionic acid.
18. The medical device of claim 1 , further comprising a top layer overlying a surface of the dried coating layer overlying the exterior surface of the medical device to reduce loss of the hydrophobic therapeutic agent during transit through a body to the tissue.
19. The medical device of claim 11 , wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, or a laser catheter.
20. The medical device of claim 11 , wherein the coating layer consists of the hydrophobic therapeutic agent and the combination of the water-soluble first additive and the water-soluble second additive.